Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/23/2026

Diagnostic Approach and Treatment for Suspected Lyme Disease

Diagnostic Testing Algorithm

  • The American College of Physicians and the Infectious Diseases Society of America recommend a two-tiered serologic testing algorithm for patients with suspected Lyme disease, consisting of an enzyme-linked immunoassay (EIA) or immunofluorescence assay (IFA), followed by a reflex Western immunoblot if the first test is positive or equivocal 1, 2
  • Testing is recommended for patients with epidemiologically plausible exposure to ticks infected with B. burgdorferi who present with meningitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathies, or spinal cord inflammation associated with painful radiculitis 3
  • The Arthritis and Rheumatology society recommends testing for patients with acute myocarditis/pericarditis of unknown cause in an appropriate epidemiologic setting 3
  • The standard two-tiered testing approach has high specificity (>98%) but lower sensitivity in early disease 1, 2

Treatment Approach for Confirmed Lyme Disease

  • The Infectious Diseases Society of America recommends oral antibiotics for 14-21 days for early localized or early disseminated disease, with doxycycline 100mg twice daily as the first-line treatment 4, 5
  • For neurologic Lyme disease, the Arthritis and Rheumatology society recommends intravenous antibiotics (ceftriaxone, cefotaxime, or penicillin G) for CNS involvement (meningitis, encephalitis) 6, 4
  • For Lyme carditis, the Arthritis and Rheumatology society recommends oral antibiotics for outpatients and initial IV ceftriaxone until clinical improvement, then switch to oral antibiotics for hospitalized patients, with a total treatment duration of 14-21 days 3, 5
  • The Praxis Medical Insights society recommends oral antibiotics for 28 days for Lyme arthritis, with consideration of a 2-4 week course of IV ceftriaxone for minimal response to initial oral therapy 4, 5

Important Clinical Considerations

  • Most patients respond well to appropriate antibiotic therapy, with a treatment failure rate of approximately 1% 5
  • Additional antibiotic therapy is not recommended for patients with persistent symptoms following standard treatment but lacking objective evidence of active infection 4, 5
  • False-positive Lyme titers can occur in patients with certain conditions (e.g., infectious mononucleosis, autoimmune diseases) 2, 7
  • Previous Lyme disease does not ensure protective immunity, and antibodies often persist for months or years after successfully treated infection 5

Lyme Disease Diagnostic Codes and Testing

Diagnostic Codes

  • The American College of Rheumatology recommends using code R21 for rash and other nonspecific skin eruption when erythema migrans is suspected but not confirmed 8
  • The American College of Rheumatology recommends using code A69.21 for meningitis due to Lyme disease for confirmed Lyme neuroborreliosis 8
  • The American College of Rheumatology recommends using code A69.22 for other neurologic disorders in Lyme disease for cranial neuropathies, radiculoneuropathy 8

Testing Approach

  • The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology recommend a two-tiered testing approach, which requires specific CPT codes, for accurate diagnosis of Lyme disease 8
  • The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology strongly recommend against routine testing in patients with psychiatric illness, dementia, Parkinson's disease, or typical ALS without epidemiologically plausible tick exposure 8
  • The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology recommend testing for specific neurologic presentations, including meningitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathies, or spinal cord inflammation with appropriate exposure history 8
  • The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology recommend against ordering testing for nonspecific symptoms without epidemiologic exposure or characteristic clinical findings 8

Lyme Disease Diagnosis and ANA Testing

Diagnostic Approach

  • The standard two‑tiered serologic algorithm (initial enzyme immunoassay or immunofluorescence assay followed by confirmatory Western blot) remains the recommended method for confirming Lyme disease, regardless of ANA results. This recommendation is based on a 2016 review of the evidence. 9
  • A positive antinuclear antibody (ANA) does not confirm, exclude, or modify the diagnosis of Lyme disease; clinicians must still apply the two‑tiered testing protocol when clinical and epidemiologic criteria are met. Evidence level: expert review. 9

Indications for Lyme Disease Testing (Independent of ANA)

  • Testing is advised when patients present with objective findings such as lymphocytic meningitis, cranial neuropathy (particularly facial palsy), radiculoneuritis, acute myocarditis or pericarditis with appropriate tick‑exposure history, or large‑joint arthritis in endemic regions. These criteria stem from the 2021 clinical guidance. Evidence level: guideline recommendation. 10
  • Serologic testing should be avoided in individuals whose presentation consists solely of nonspecific symptoms, isolated psychiatric illness, or classic manifestations of neurodegenerative disorders (e.g., ALS, multiple sclerosis, Parkinson’s disease, dementia), especially when there is no documented tick exposure in an endemic area. This guidance is derived from the 2021 recommendations. Evidence level: guideline recommendation. 10

REFERENCES

4

Treatment of Lyme Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Treatment for Untreated Lyme Disease Diagnosed Through Bloodwork [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025